文献速递造血干细胞移植与细胞治疗

慢性移植物抗宿主病治疗的新靶点

Novel targets in the treatment of chronic graft-versus-host disease.
PubMed 文献 · Leukemia · 2016-11-30

综述总结慢性移植物抗宿主病(GVHD)治疗的新靶点与在研临床开发。当前对激素难治性慢性GVHD疗效有限且缺乏FDA或EMA批准药物;对慢性GVHD生物学的深入理解、诊断与临床试验设计指南以及肿瘤与免疫学药物研发的激增共同推动了该领域药物开发与临床研究。

要点

  • 慢性GVHD仍是异基因造血干细胞移植后晚期并发症和死亡的主要原因。
  • 激素难治性慢性GVHD现有治疗选择疗效有限,且缺乏FDA或EMA批准药物。
  • 对慢性GVHD生物学的理解及诊断与临床试验设计指南为研究提供共同语言和路径。

核心结论

  • 对慢性GVHD生物学的深入理解已提供新的治疗靶点,诊断与临床试验设计的结构化指南为研究提供共同语言和路径;肿瘤与免疫学药物研发的激增推动了该领域药物开发与临床研究。

研究设计与样本

  • 综述总结慢性GVHD新疗法的在研临床开发。

主要发现

  • 慢性GVHD仍是异基因造血干细胞移植后晚期并发症和死亡的主要原因。
  • 激素难治性慢性GVHD现有治疗选择疗效有限,且缺乏指导管理决策的稳健数据。
  • 缺乏美国食品药品监督管理局(FDA)或欧洲药品管理局(EMA)批准的GVHD药物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advances that have improved survival after allogeneic hematopoietic stem cell transplantation (HCT), chronic graft-versus-host disease (GVHD) remains a leading cause of late morbidity and mortality after transplant. Current treatment options show limited efficacy in steroid-refractory disease, and there exists a paucity of robust data to guide management decisions. Lack of United States Food and Drug Administration (FDA)- or European Medicines Agency (EMA)-approved agents in GVHD underscore the importance of developing novel therapies. Better understanding of the biology of chronic GVHD has provided novel targets for treatment, and structured guidelines in diagnosis and in clinical trial design have provided a common language and pathways for research in this area. These, combined with the surge of drug development in Oncology and Immunology, are factors that have contributed to the accelerating field of drug development and clinical research in chronic GVHD. In these exciting times, it is possible to foresee long awaited advances in the treatment of this devastating complication of HCT. This review will summarize the ongoing clinical development for novel therapies in chronic GVHD.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Im A, Hakim FT, Pavletic SZ, et al. Novel targets in the treatment of chronic graft-versus-host disease. Leukemia. 2016. PMID: 27899803. doi:10.1038/leu.2016.367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。